{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:49:21Z","timestamp":1794412161538,"version":"4.9.0"},"reference-count":68,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Metastatic Triple-negative Breast Cancer (mTNBC) is the most aggressive\nform of breast cancer, with a greater risk of metastasis and recurrence. Research studies have\npublished in-depth analyses of the advantages and disadvantages of pembrolizumab, and early data\nfrom numerous trials suggests that patients with mTNBC have had remarkable outcomes. This\nmeta-analysis compares the data from numerous relevant studies in order to evaluate the safety\nand efficacy of pembrolizumab monotherapy or combination therapies for mTNBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>To identify eligible RCTs, a thorough literature search was carried out using electronic\ndatabases. CMA software was utilized to perform heterogeneity tests using fixed and random-effects\nmodels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>According to our pooled data, the median Progression-free Survival (PFS) was 2.66\nmonths, and the median overall survival (OS) was 12.26 months. Furthermore, by comparing efficacy\nindicators between PD-L1\u2013positive and PD-L1\u2013negative groups, a correlation was found between\nthe overexpression of PD-L1 with OS, PFS, and ORR. Patients with PD-L1-positive tumors\nhad a higher response rate, with an ORR of 21.1%, compared to the patients with PD-L1-negative\ntumors. The ORR for first-line immunotherapy was higher than that of \u2265second-line immunotherapy.\nIn addition, pembrolizumab plus combination treatment resulted in a pooled incidence of immune-\nrelated adverse events of 22.7%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>A modest response to pembrolizumab monotherapy was detected in the mTNBC patients.\nFurthermore, a better outcome from pembrolizumab treatment may be predicted by PD-L1--\npositive status, non-liver\/lung metastases, combination therapy, and first-line immunotherapy.\nPembrolizumab, in combination with chemotherapy, may be more beneficial for patients whose tumors\nare PD-L1 positive.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115665232283880240301035621","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T03:02:57Z","timestamp":1710212577000},"page":"72-88","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.2174","volume":"25","author":[{"given":"Mahmood","family":"Araghi","sequence":"first","affiliation":[{"name":"Department of Pathology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Gharebakhshi","sequence":"additional","affiliation":[{"name":"Department of\nRadiology, School of Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Faramarzi","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Mafi","sequence":"additional","affiliation":[{"name":"Department\nof Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical\nSciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahoora","family":"Mousavi","sequence":"additional","affiliation":[{"name":"Molecular and Cell Biology Research Center (MCBRC), Hemoglobinopathy Institute, Mazandaran\nUniversity of Medical Sciences, Sari, Iran"},{"name":"Medical Sciences Technologies, Molecular and Cell Biology Research\nCenter (MCBRC), Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Alimohammadi","sequence":"additional","affiliation":[{"name":"Student Research\nCommittee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences,\nTehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Soleimantabar","sequence":"additional","affiliation":[{"name":"Department of\nRadiology, School of Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"Yin L.","year":"2020","unstructured":"Yin L.; Duan J.J.; Bian X.W.; Yu S.; Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res  2020,22(1),61","journal-title":"Breast Cancer Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"Kennecke H.","year":"2010","unstructured":"Kennecke H.; Yerushalmi R.; Woods R.; Cheang M.C.U.; Voduc D.; Speers C.H.; Nielsen T.O.; Gelmon K.; Metastatic behavior of breast cancer subtypes. J Clin Oncol  2010,28(20),3271-3277","journal-title":"J Clin Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10787-021-00817-8","volume":"29","author":"Alimohammadi M.","year":"2021","unstructured":"Alimohammadi M.; Rahimi A.; Faramarzi F.; Golpour M.; Shakib J.R.; Navaei A.R.; Rafiei A.; Effects of coenzyme Q10 supplementation on inflammation, angiogenesis, and oxidative stress in breast cancer patients: A systematic review and meta-analysis of randomized controlled- trials. Inflammopharmacology  2021,29(3),579-593","journal-title":"Inflammopharmacology"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","volume":"69","author":"Miller K.D.","year":"2019","unstructured":"Miller K.D.; Nogueira L.; Mariotto A.B.; Rowland J.H.; Yabroff K.R.; Alfano C.M.; Jemal A.; Kramer J.L.; Siegel R.L.; Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin  2019,69(5),363-385","journal-title":"CA Cancer J Clin"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1200\/EDBK_159135","volume":"35","author":"Anders C.K.","year":"2016","unstructured":"Anders C.K.; Abramson V.; Tan T.; Dent R.; The evolution of triple-negative breast cancer: From biology to novel therapeutics. Am Soc Clin Oncol Educ Book  2016,35(36),34-42","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.canlet.2018.10.042","volume":"442","author":"Wang X.","year":"2019","unstructured":"Wang X.; Qi Y.; Kong X.; Zhai J.; Li Y.; Song Y.; Wang J.; Feng X.; Fang Y.; Immunological therapy: A novel thriving area for triple-negative breast cancer treatment. Cancer Lett  2019,442,409-428","journal-title":"Cancer Lett"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"8878","DOI":"10.3390\/ijms23168878","volume":"23","author":"Ren Y.","year":"2022","unstructured":"Ren Y.; Song J.; Li X.; Luo N.; Rationale and clinical research progress on PD-1\/PD-L1-based immunotherapy for metastatic triple-negative breast cancer. Int J Mol Sci  2022,23(16),8878","journal-title":"Int J Mol Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"653521","DOI":"10.3389\/fphar.2021.653521","volume":"12","author":"Qi Y.","year":"2021","unstructured":"Qi Y.; Zhang L.; Wang Z.; Kong X.; Zhai J.; Fang Y.; Wang J.; Efficacy and safety of Anti-PD-1\/ PD-L1 monotherapy for metastatic breast cancer: Clinical evidence. Front Pharmacol  2021,12,653521","journal-title":"Front Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-022-06665-6","volume":"195","author":"Howard F.M.","year":"2022","unstructured":"Howard F.M.; Pearson A.T.; Nanda R.; Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat  2022,195(1),1-15","journal-title":"Breast Cancer Res Treat"},{"key":"ref=10","first-page":"1","volume":"8","author":"Abdou Y.","year":"2022","unstructured":"Abdou Y.; Goudarzi A.; Yu J.X.; Upadhaya S.; Vincent B.; Carey L.A.; Immunotherapy in triple negative breast cancer: Beyond checkpoint inhibitors. npj. Breast Cancer  2022,8(1),1-10","journal-title":"Breast Cancer"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"Twomey J.D.","year":"2021","unstructured":"Twomey J.D.; Zhang B.; Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J  2021,23(2),39","journal-title":"AAPS J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"Larkin J.","year":"2015","unstructured":"Larkin J.; Sileni C.V.; Gonzalez R.; Grob J.J.; Cowey C.L.; Lao C.D.; Schadendorf D.; Dummer R.; Smylie M.; Rutkowski P.; Ferrucci P.F.; Hill A.; Wagstaff J.; Carlino M.S.; Haanen J.B.; Maio M.; Rodas M.I.; McArthur G.A.; Ascierto P.A.; Long G.V.; Callahan M.K.; Postow M.A.; Grossmann K.; Sznol M.; Dreno B.; Bastholt L.; Yang A.; Rollin L.M.; Horak C.; Hodi F.S.; Wolchok J.D.; Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med  2015,373(1),23-34","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1634\/theoncologist.2016-0496","volume":"22","author":"Larkins E.","year":"2017","unstructured":"Larkins E.; Blumenthal G.M.; Yuan W.; He K.; Sridhara R.; Subramaniam S.; Zhao H.; Liu C.; Yu J.; Goldberg K.B.; McKee A.E.; Keegan P.; Pazdur R.; FDA approval summary: Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist  2017,22(7),873-878","journal-title":"Oncologist"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"Robert C.","year":"2015","unstructured":"Robert C.; Long G.V.; Brady B.; Dutriaux C.; Maio M.; Mortier L.; Hassel J.C.; Rutkowski P.; McNeil C.; Warzocha K.E.; Savage K.J.; Hernberg M.M.; Lebb\u00e9 C.; Charles J.; Mihalcioiu C.; Sileni C.V.; Mauch C.; Cognetti F.; Arance A.; Schmidt H.; Schadendorf D.; Gogas H.; Eriksson L.L.; Horak C.; Sharkey B.; Waxman I.M.; Atkinson V.; Ascierto P.A.; Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med  2015,372(4),320-330","journal-title":"N Engl J Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"Topalian S.L.","year":"2012","unstructured":"Topalian S.L.; Hodi F.S.; Brahmer J.R.; Gettinger S.N.; Smith D.C.; McDermott D.F.; Powderly J.D.; Carvajal R.D.; Sosman J.A.; Atkins M.B.; Leming P.D.; Spigel D.R.; Antonia S.J.; Horn L.; Drake C.G.; Pardoll D.M.; Chen L.; Sharfman W.H.; Anders R.A.; Taube J.M.; McMiller T.L.; Xu H.; Korman A.J.; Jure-Kunkel M.; Agrawal S.; McDonald D.; Kollia G.D.; Gupta A.; Wigginton J.M.; Sznol M.; Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med  2012,366(26),2443-2454","journal-title":"N Engl J Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"Topalian S.L.","year":"2014","unstructured":"Topalian S.L.; Sznol M.; McDermott D.F.; Kluger H.M.; Carvajal R.D.; Sharfman W.H.; Brahmer J.R.; Lawrence D.P.; Atkins M.B.; Powderly J.D.; Leming P.D.; Lipson E.J.; Puzanov I.; Smith D.C.; Taube J.M.; Wigginton J.M.; Kollia G.D.; Gupta A.; Pardoll D.M.; Sosman J.A.; Hodi F.S.; Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol  2014,32(10),1020-1030","journal-title":"J Clin Oncol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/13543784.2022.2009456","volume":"31","author":"Rizzo A.","year":"2022","unstructured":"Rizzo A.; Ricci A.D.; Lanotte L.; Lombardi L.; Federico D.A.; Brandi G.; Caldarola G.G.; Immune-based combinations for metastatic triple negative breast cancer in clinical trials: Current knowledge and therapeutic prospects. Expert Opin Investig Drugs  2022,31(6),557-565","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=18","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221086916","volume":"14.","author":"Huppert L.A.","year":"2022","unstructured":"Huppert L.A.; Gumusay O.; Rugo H.S.; Emerging treatment strategies for metastatic triple-negative breast cancer. Ther Adv Med Oncol  2022,14.","journal-title":"Ther Adv Med Oncol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.2174\/0113816128270102231016110637","volume":"29","author":"Alimohammadi M.","year":"2023","unstructured":"Alimohammadi M.; Faramarzi F.; Mafi A.; Mousavi T.; Rahimi A.; Mirzaei H.; Asemi Z.; Efficacy and safety of atezolizumab monotherapy or combined therapy with chemotherapy in patients with metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized controlled trials. Curr Pharm Des  2023,29(31),2461-2476","journal-title":"Curr Pharm Des"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"Demaria S.","year":"2015","unstructured":"Demaria S.; Golden E.B.; Formenti S.C.; Role of local radiation therapy in cancer immunotherapy. JAMA Oncol  2015,1(9),1325-1332","journal-title":"JAMA Oncol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"Fukumura D.","year":"2018","unstructured":"Fukumura D.; Kloepper J.; Amoozgar Z.; Duda D.G.; Jain R.K.; Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol  2018,15(5),325-340","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","volume":"44","author":"Pfirschke C.","year":"2016","unstructured":"Pfirschke C.; Engblom C.; Rickelt S.; Cortez-Retamozo V.; Garris C.; Pucci F.; Yamazaki T.; Colame P.V.; Newton A.; Redouane Y.; Lin Y.J.; Wojtkiewicz G.; Iwamoto Y.; Mino-Kenudson M.; Huynh T.G.; Hynes R.O.; Freeman G.J.; Kroemer G.; Zitvogel L.; Weissleder R.; Pittet M.J.; Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity  2016,44(2),343-354","journal-title":"Immunity"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"919072","DOI":"10.3389\/fonc.2022.919072","volume":"12","author":"Luo C.","year":"2022","unstructured":"Luo C.; Wang P.; He S.; Zhu J.; Shi Y.; Wang J.; Progress and prospect of immunotherapy for triple-negative breast cancer. Front Oncol  2022,12,919072","journal-title":"Front Oncol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1080\/17512433.2022.2142559","volume":"15","author":"Uliano J","year":"2022","unstructured":"Uliano J; Nicol\u00f2 E; Corvaja C; Salimbeni T.B; Trapani D; Curigliano G.; Combination immunotherapy strategies for triple-negative breast cancer: Current progress and barriers within the pharmacological landscape. Expert Rev Clin Pharmacol  2022,15(12),1399-1413","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"Hodi F.S.","year":"2016","unstructured":"Hodi F.S.; Chesney J.; Pavlick A.C.; Robert C.; Grossmann K.F.; McDermott D.F.; Linette G.P.; Meyer N.; Giguere J.K.; Agarwala S.S.; Shaheen M.; Ernstoff M.S.; Minor D.R.; Salama A.K.; Taylor M.H.; Ott P.A.; Horak C.; Gagnier P.; Jiang J.; Wolchok J.D.; Postow M.A.; Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol  2016,17(11),1558-1568","journal-title":"Lancet Oncol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"Gandhi L.","year":"2018","unstructured":"Gandhi L.; Abreu R.D.; Gadgeel S.; Esteban E.; Felip E.; De Angelis F.; Domine M.; Clingan P.; Hochmair M.J.; Powell S.F.; Cheng S.Y.S.; Bischoff H.G.; Peled N.; Grossi F.; Jennens R.R.; Reck M.; Hui R.; Garon E.B.; Boyer M.; Viqueira R.B.; Novello S.; Kurata T.; Gray J.E.; Vida J.; Wei Z.; Yang J.; Raftopoulos H.; Pietanza M.C.; Garassino M.C.; Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med  2018,378(22),2078-2092","journal-title":"N Engl J Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"Cortes J.","year":"2020","unstructured":"Cortes J.; Cescon D.W.; Rugo H.S.; Nowecki Z.; Im S.A.; Yusof M.M.; Gallardo C.; Lipatov O.; Barrios C.H.; Holgado E.; Iwata H.; Masuda N.; Otero M.T.; Gokmen E.; Loi S.; Guo Z.; Zhao J.; Aktan G.; Karantza V.; Schmid P.; Luis F.; Gonzalo G.A.; Diego K.; Ruben K.; Matias M.; Mirta V.; Sally B-H.; Stephen B.; Philip C.; Sherene L.; Dhanusha S.; Andrea G.; Donatienne T.; Carlos B.; Leandro B.; Fabiano C.; Ruffo F.J.; Roberto H.; Carvalho D.L.; Toniazzi F.C.L.; Odebrecht R.R.; Orlando A.S.N.; Felipe S.; David C.; Danielle C.; Cristiano F.; Xinni S.; Joanne Y.; Alejandro A.; Carlos G.; Claudio S.; Cesar S.; Eduardo Y.; Alvaro G.D.; Jesus S.; Petra H.; Zdenek K.; Bohuslav M.; Katarina P.; Jana P.; Vesna G.; Erik J.; Jeanette J.; Soren L.; Tamas L.; Herve B.; Isabelle D.; Anthony G.; Anne-Claire H-B.; Luis T.; Jens-Uwe B.; Peter F.; Dirk F.; Nadia H.; Jens H.; Anna K.F.S.; Christian K.; Sibylle L.; Diana L.; Tjoung-Won P-S.; Raquel Von S.; Pauline W.; Louis C.; Ava K.; Roger K.C.N.; Peter A.; Tibor C.; Zsuzsanna K.; Laszlo L.; Karoly M.; Gabor R.; John C.; Catherine K.; Seamus O.R.; Saverio C.; Antonietta D.A.; Enrico R.; Tomoyuki A.; Takaaki F.; Kenichi I.; Takashi I.; Yoshinori I.; Tsutomu I.; Hiroji I.; Yoshimasa K.; Koji M.; Yasuo M.; Hirofumi M.; Seigo N.; Naoki N.; Shoichiro O.; Akihiko O.; Yasuaki S.; Eiji S.; Masato T.; Yuko T.; Kenji T.; Koichiro T.; Junichiro W.; Naohito Y.; Yutaka Y.; Teruo Y.; Anita B.; Mastura M.Y.; Angel G.V.; Alejandro J.R.; Jorge M.R.; Flavia M-V.; Jessica R.C.; Karin B.; Vivianne T-H.; David P.; Ewa C.; Ewa N-Z.; Zbigniew N.; Barbara R.; Joanna S.; Cezary S.; Rafal T.; Bogdan Z.; Alexander A.; Natalia F.; Oleg L.; Andrey M.; Vladimir M.; Guzel M.; Jin Hee A.; Seock-Ah I.; Keun Seok L.; Kwong Hwa P.; Yeon Hee P.; Begona B.H.; Javier C.; Josefina C.J.; Luis C.M.; Jose G.S.; Maria G.; Esther H.; Esther Z.A.; Chien-Ting L.; Mei-Ching L.; Chiun-Sheng H.; Chao-Jung T.; Ling-Ming T.; Cagatay A.; Gul B.; Irfan C.; Erhan G.; Seyda G.; Nil M.M.; Mustafa O.; Ozgur O.; Sinan Y.; Steve C.; Janine G.; Iain M.P.; Peter S.; Nicholas T.; Mark T.; Christopher T.; Duncan W.; Hryhoriy A.; Oleksandr B.; Igor B.; Oleksii K.; Olena K.; Hanna K.; Anna K.; Iurii L.; Alla N.; Natalya O.; Olga P.; Andrii R.; Sergii S.; Yaroslav S.; Dmytro T.; Grygorii U.; Ihor V.; Sibel B.; Madhu C.; Michael C.; Patrick C.; Scott C.; Jennifer D.; Keerthi G.; Jeffrey H.; Kent H.; William I.; Randa L.; Janice L.; Raul M.; Susan M.; Rita N.; Ira O.; Coral O.; Timothy P.; Amit P.; Brian P.; Hope R.; Irina R.; Michael S.; Robert S.; Michael S.; Laura S.; Bradley S.; Michaela T.; Frances V-A.; Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet  2020,396(10265),1817-1828","journal-title":"Lancet"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.annonc.2020.01.072","volume":"31","author":"Schmid P.","year":"2020","unstructured":"Schmid P.; Salgado R.; Park Y.H.; Mu\u00f1oz-Couselo E.; Kim S.B.; Sohn J.; Im S.A.; Foukakis T.; Kuemmel S.; Dent R.; Yin L.; Wang A.; Tryfonidis K.; Karantza V.; Cort\u00e9s J.; Loi S.; Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol  2020,31(5),569-581","journal-title":"Ann Oncol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"v859","DOI":"10.1093\/annonc\/mdz394.010","volume":"30","author":"Cort\u00e9s J.","year":"2019","unstructured":"Cort\u00e9s J.; Lipatov O.; Im S-A.; Gon\u00e7alves A.; Lee K.S.; Schmid P.; Tamura K.; Testa L.; Witzel I.; Ohtani S.; Zambelli S.; Harbeck N.; Andr\u00e9 F.; Dent R.; Zhou X.; Karantza V.; Mejia J.A.; Winer E.P.; KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Ann Oncol  2019,30,v859-v860","journal-title":"Ann Oncol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1758835920940928","DOI":"10.1177\/1758835920940928","volume":"12","author":"Zou Y.","year":"2020","unstructured":"Zou Y.; Zou X.; Zheng S.; Tang H.; Zhang L.; Liu P.; Xie X.; Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: A systematic review and meta-analysis. Ther Adv Med Oncol  2020,12,1758835920940928","journal-title":"Ther Adv Med Oncol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1758835920909091","DOI":"10.1177\/1758835920909091","volume":"12","author":"Simmons C.E.","year":"2020","unstructured":"Simmons C.E.; Brezden-Masley C.; McCarthy J.; McLeod D.; Joy A.A.; Positive progress: Current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. Ther Adv Med Oncol  2020,12,1758835920909091","journal-title":"Ther Adv Med Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.20944\/preprints202105.0546.v1","volume":"22","author":"Amin M","year":"2021","unstructured":"Amin M; Sharif S; Asghar W; Sadaf H; Sarfraz A; Sarfraz Z; Atezolizumab and pembrolizumab in triple-negative breast cancer: A meta-analysis. Expert Rev Anticancer Ther  2021,22(2),229-235","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"Brahmer J.R.","year":"2018","unstructured":"Brahmer J.R.; Lacchetti C.; Schneider B.J.; Atkins M.B.; Brassil K.J.; Caterino J.M.; Chau I.; Ernstoff M.S.; Gardner J.M.; Ginex P.; Hallmeyer S.; Chakrabarty H.J.; Leighl N.B.; Mammen J.S.; McDermott D.F.; Naing A.; Nastoupil L.J.; Phillips T.; Porter L.D.; Puzanov I.; Reichner C.A.; Santomasso B.D.; Seigel C.; Spira A.; Almazor S.M.E.; Wang Y.; Weber J.S.; Wolchok J.D.; Thompson J.A.; Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol  2018,36(17),1714-1768","journal-title":"J Clin Oncol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"Postow M.A.","year":"2018","unstructured":"Postow M.A.; Sidlow R.; Hellmann M.D.; Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med  2018,378(2),158-168","journal-title":"N Engl J Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"Vinayak S.","year":"2019","unstructured":"Vinayak S.; Tolaney S.M.; Schwartzberg L.; Mita M.; McCann G.; Tan A.R.; Hendrickson W.A.E.; Forero A.; Anders C.; Wulf G.M.; Dillon P.; Lynce F.; Zarwan C.; Erban J.K.; Zhou Y.; Buerstatte N.; Graham J.R.; Arora S.; Dezube B.J.; Telli M.L.; Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol  2019,5(8),1132-1140","journal-title":"JAMA Oncol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"Liberati A.","year":"2009","unstructured":"Liberati A.; Altman D.G.; Tetzlaff J.; Mulrow C.; G\u00f8tzsche P.C.; Ioannidis J.P.A.; Clarke M.; Devereaux P.J.; Kleijnen J.; Moher D.; The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ  2009,339,b2700","journal-title":"BMJ"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"Higgins J.P.T.","year":"2011","unstructured":"Higgins J.P.T.; Altman D.G.; G\u00f8tzsche P.C.; J\u00fcni P.; Moher D.; Oxman A.D.; Savovic J.; Schulz K.F.; Weeks L.; Sterne J.A.C.; The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ  2011,343(oct18 2),d5928","journal-title":"BMJ"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"155691","DOI":"10.1016\/j.cyto.2021.155691","volume":"148","author":"Alimohammadi M.","year":"2021","unstructured":"Alimohammadi M.; Rahimi A.; Faramarzi F.; Navaei A.R.; Rafiei A.; Overexpression of chemokine receptor CXCR4 predicts lymph node metastatic risk in patients with melanoma: A systematic review and meta-analysis. Cytokine  2021,148,155691","journal-title":"Cytokine"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/cam4.106","volume":"2","author":"McDermott D.F.","year":"2013","unstructured":"McDermott D.F.; Atkins M.B.;  -1 as a potential target in cancer therapy. Cancer Med  2013,2(5),662-673","journal-title":"Cancer Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/13543784.2022.2008354","volume":"31","author":"Rizzo A.","year":"2022","unstructured":"Rizzo A.; Ricci A.D.; Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs  2022,31(6),549-555","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.gendis.2022.07.024","volume":"10","author":"Kumar S.","year":"2023","unstructured":"Kumar S.; Chatterjee M.; Ghosh P.; Ganguly K.K.; Basu M.; Ghosh M.K.; Targeting PD-1\/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes Dis  2023,10(4),1318-1350","journal-title":"Genes Dis"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"Nanda R.","year":"2016","unstructured":"Nanda R.; Chow L.Q.M.; Dees E.C.; Berger R.; Gupta S.; Geva R.; Pusztai L.; Pathiraja K.; Aktan G.; Cheng J.D.; Karantza V.; Buisseret L.; Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol  2016,34(21),2460-2467","journal-title":"J Clin Oncol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"P6-10-03","DOI":"10.1158\/1538-7445.SABCS16-P6-10-03","volume":"77","author":"Nanda R","year":"2017","unstructured":"Nanda R; Specht J; Dees C; Berger R; Gupta S; Geva R; Abstract P6-10-03: KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC). Cancer Res  2017,77(S4),P6-10-03","journal-title":"Cancer Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","volume":"30","author":"Adams S.","year":"2019","unstructured":"Adams S.; Schmid P.; Rugo H.S.; Winer E.P.; Loirat D.; Awada A.; Cescon D.W.; Iwata H.; Campone M.; Nanda R.; Hui R.; Curigliano G.; Toppmeyer D.; O\u2019Shaughnessy J.; Loi S.; Shimon P.S.; Tan A.R.; Card D.; Zhao J.; Karantza V.; Cort\u00e9s J.; Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Ann Oncol  2019,30(3),397-404","journal-title":"Ann Oncol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"Adams S.","year":"2019","unstructured":"Adams S.; Loi S.; Toppmeyer D.; Cescon D.W.; De Laurentiis M.; Nanda R.; Winer E.P.; Mukai H.; Tamura K.; Armstrong A.; Liu M.C.; Iwata H.; Ryvo L.; Wimberger P.; Rugo H.S.; Tan A.R.; Jia L.; Ding Y.; Karantza V.; Schmid P.; Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Ann Oncol  2019,30(3),405-411","journal-title":"Ann Oncol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"Sharma P.","year":"2017","unstructured":"Sharma P.; Lieskovan H.S.; Wargo J.A.; Ribas A.; Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell  2017,168(4),707-723","journal-title":"Cell"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2217\/imt-2022-0082","volume":"14","author":"Huang M.","year":"2022","unstructured":"Huang M.; Fasching P.; Haiderali A.; Pan W.; Gray E.; Zhou Z.Y.; Hu P.; Chaudhuri M.; Tilleghem B.D.C.L.; Cappoen N.; O\u2019Shaughnessy J.; Cost\u2013effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer. Immunotherapy  2022,14(13),1027-1041","journal-title":"Immunotherapy"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"Bianchini G.","year":"2022","unstructured":"Bianchini G.; De Angelis C.; Licata L.; Gianni L.; Treatment landscape of triple-negative breast cancer \u2014 expanded options, evolving needs. Nat Rev Clin Oncol  2022,19(2),91-113","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"796","DOI":"10.53350\/pjmhs22167796","volume":"16","author":"Rehman M.U.U.","year":"2022","unstructured":"Rehman M.U.U.; Ali I.; Zia H.; Pembrolizumab and chemotherapy with radiology comparative analysis in patients with untreated metastatic triple negative breast cancer. Pak J Med Health Sci  2022,16(07),796","journal-title":"Pak J Med Health Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.3390\/curroncol29070377","volume":"29","author":"Pauls M.","year":"2022","unstructured":"Pauls M.; Chia S.; LeVasseur N.; Current and new novel combination treatments for metastatic triple-negative breast cancer. Curr Oncol  2022,29(7),4748-4767","journal-title":"Curr Oncol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"Emens L.A.","year":"2015","unstructured":"Emens L.A.; Middleton G.; The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunol Res  2015,3(5),436-443","journal-title":"Cancer Immunol Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"Winer E.P.","year":"2021","unstructured":"Winer E.P.; Lipatov O.; Im S.A.; Goncalves A.; Couselo M.E.; Lee K.S.; Schmid P.; Tamura K.; Testa L.; Witzel I.; Ohtani S.; Turner N.; Zambelli S.; Harbeck N.; Andre F.; Dent R.; Zhou X.; Karantza V.; Mejia J.; Cortes J.; Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): A randomised, open-label, phase 3 trial. Lancet Oncol  2021,22(4),499-511","journal-title":"Lancet Oncol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-20-4726","volume":"27","author":"Tolaney S.M.","year":"2021","unstructured":"Tolaney S.M.; Kalinsky K.; Kaklamani V.G.; D\u2019Adamo D.R.; Aktan G.; Tsai M.L.; O\u2019Regan R.M.; Kaufman P.A.; Wilks S.T.; Andreopoulou E.; Patt D.A.; Yuan Y.; Wang G.; Savulsky C.; Xing D.; Kleynerman E.; Karantza V.; Diab S.; Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): A phase Ib\/II study. Clin Cancer Res  2021,27(11),3061-3068","journal-title":"Clin Cancer Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"e0157164","DOI":"10.1371\/journal.pone.0157164","volume":"11","author":"Young K.H.","year":"2016","unstructured":"Young K.H.; Baird J.R.; Savage T.; Cottam B.; Friedman D.; Bambina S.; Messenheimer D.J.; Fox B.; Newell P.; Bahjat K.S.; Gough M.J.; Crittenden M.R.; Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS One  2016,11(6),e0157164","journal-title":"PLoS One"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"Dovedi S.J.","year":"2014","unstructured":"Dovedi S.J.; Adlard A.L.; Lipowska-Bhalla G.; McKenna C.; Jones S.; Cheadle E.J.; Stratford I.J.; Poon E.; Morrow M.; Stewart R.; Jones H.; Wilkinson R.W.; Honeychurch J.; Illidge T.M.; Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res  2014,74(19),5458-5468","journal-title":"Cancer Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fonc.2018.00612","volume":"8","author":"Buchwald Z.S.","year":"2018","unstructured":"Buchwald Z.S.; Wynne J.; Nasti T.H.; Zhu S.; Mourad W.F.; Yan W.; Gupta S.; Khleif S.N.; Khan M.K.; Radiation, immune checkpoint blockade and the abscopal effect: A critical review on timing, dose and fractionation. Front Oncol  2018,8,612","journal-title":"Front Oncol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","volume":"20","author":"Esteva F.J.","year":"2019","unstructured":"Esteva F.J.; Hubbard-Lucey V.M.; Tang J.; Pusztai L.; Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol  2019,20(3),e175-e186","journal-title":"Lancet Oncol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","volume":"36","author":"Luke J.J.","year":"2018","unstructured":"Luke J.J.; Lemons J.M.; Karrison T.G.; Pitroda S.P.; Melotek J.M.; Zha Y.; Al-Hallaq H.A.; Arina A.; Khodarev N.N.; Janisch L.; Chang P.; Patel J.D.; Fleming G.F.; Moroney J.; Sharma M.R.; White J.R.; Ratain M.J.; Gajewski T.F.; Weichselbaum R.R.; Chmura S.J.; Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol  2018,36(16),1611-1618","journal-title":"J Clin Oncol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/cncr.32599","volume":"126","author":"Ho A.Y.","year":"2020","unstructured":"Ho A.Y.; Barker C.A.; Arnold B.B.; Powell S.N.; Hu Z.I.; Gucalp A.; Zapata L.L.; Wen H.Y.; Kallman C.; D\u2019Agnolo A.; Zhang Z.; Flynn J.; Dunn S.A.; McArthur H.L.; A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer  2020,126(4),850-860","journal-title":"Cancer"},{"key":"ref=60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.1008","volume":"35","author":"Adams S.","year":"2017","unstructured":"Adams S.; Schmid P.; Rugo H.S.; Winer E.P.; Loirat D.; Awada A.; Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. Clin Oncol  2017,35(15)","journal-title":"Clin Oncol"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2018.36.15_suppl.1011","volume":"36","author":"Vinayak S.","year":"2018","unstructured":"Vinayak S.; Tolaney S.M.; Schwartzberg L.S.; Mita M.M.; McCann G.A-L.; Tan A.R.; TOPACIO\/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. J Clin Oncol  2018,36(15),1011","journal-title":"J Clin Oncol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41467-020-15364-z","volume":"11","author":"Qin G.","year":"2020","unstructured":"Qin G.; Wang X.; Ye S.; Li Y.; Chen M.; Wang S.; Qin T.; Zhang C.; Li Y.; Long Q.; Hu H.; Shi D.; Li J.; Zhang K.; Zhai Q.; Tang Y.; Kang T.; Lan P.; Xie F.; Lu J.; Deng W.; NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer. Nat Commun  2020,11(1),1669","journal-title":"Nat Commun"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/1753465816636557","volume":"10","author":"Abdel-Rahman O.","year":"2016","unstructured":"Abdel-Rahman O.; Fouad M.; Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Ther Adv Respir Dis  2016,10(3),183-193","journal-title":"Ther Adv Respir Dis"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","volume":"363","author":"Xu C.","year":"2018","unstructured":"Xu C.; Chen Y.P.; Du X.J.; Liu J.Q.; Huang C.L.; Chen L.; Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis. BMJ  2018,363,k4226","journal-title":"BMJ"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Wang Y.","year":"2019","unstructured":"Wang Y.; Zhou S.; Yang F.; Qi X.; Wang X.; Guan X.; Shen C.; Duma N.; Aguilera V.J.; Chintakuntlawar A.; Price K.A.; Molina J.R.; Pagliaro L.C.; Halfdanarson T.R.; Grothey A.; Markovic S.N.; Nowakowski G.S.; Ansell S.M.; Wang M.L.; Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncol  2019,5(7),1008-1019","journal-title":"JAMA Oncol"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/JIPO.JIPO_20_18","volume":"1","author":"Naing A.","year":"2018","unstructured":"Naing A.; Being realistic and optimistic in curing cancer. J Immunother Precis Oncol  2018,1(2),53-55","journal-title":"J Immunother Precis Oncol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"Schmid P.","year":"2020","unstructured":"Schmid P.; Cortes J.; Pusztai L.; McArthur H.; K\u00fcmmel S.; Bergh J.; Denkert C.; Park Y.H.; Hui R.; Harbeck N.; Takahashi M.; Foukakis T.; Fasching P.A.; Cardoso F.; Untch M.; Jia L.; Karantza V.; Zhao J.; Aktan G.; Dent R.; O\u2019Shaughnessy J.; Pembrolizumab for early triple-negative breast cancer. N Engl J Med  2020,382(9),810-821","journal-title":"N Engl J Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"e000173","DOI":"10.1136\/jitc-2019-000173","volume":"8","author":"Shah A.N.","year":"2020","unstructured":"Shah A.N.; Flaum L.; Helenowski I.; Santa-Maria C.A.; Jain S.; Rademaker A.; Nelson V.; Tsarwhas D.; Cristofanilli M.; Gradishar W.; Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2\u2212negative endocrine-refractory metastatic breast cancer. J Immunother Cancer  2020,8(1),e000173","journal-title":"J Immunother Cancer"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115665232283880240301035621","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/227872\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115665232283880240301035621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T06:53:33Z","timestamp":1729666413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/227872\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115665232283880240301035621","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}